Loading
No description yet: the sentence for this tag has not been written. 2 records carry it: 2 trials.
| Cancers | Other tags | ||||
|---|---|---|---|---|---|
ASCOT (JCOG1202) In Japan, six months of the oral chemotherapy S-1 after surgery for bile duct, gallbladder or ampullary cancer improved three-year survival from 68 to 77 percent. S-1 is not licensed for this use in the UK or Europe, so the result cannot be applied directly to NHS patients. | Gallbladder cancer, Biliary tract cancer, Extrahepatic cholangiocarcinoma | none | |||
CREATE-X CREATE-X showed that giving the tablet chemotherapy capecitabine for six months after surgery, to women whose breast cancer had not fully disappeared with pre-operative chemotherapy, cut deaths; the gain was largest in triple-negative disease, where five-year survival rose from 70 to 79 percent. | Triple-negative breast cancer, Early triple-negative breast cancer, HR-positive / HER2-negative breast cancer | none |